Rocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story

Rocket Pharma (RCKT) announced an update on their ongoing clinical study.

Rocket Pharmaceuticals Inc. (RCKT) has launched a new study called “An Observational Study of Patients With Dilated Cardiomyopathy (DCM) Associated With Pathogenic BAG3 Variants.” The goal is to track how this rare genetic heart disease progresses in adults, building a clearer picture that can guide future gene therapy programs and long-term treatment planning.

This study is not testing a new drug or gene therapy directly. Instead, it follows patients with BAG3-related DCM over time, so Rocket can better design future trials and pick the right outcomes, dosing windows, and patient groups for its pipeline treatments.

The study is observational and cohort-based, meaning it simply watches and records patient outcomes. There is no randomization, no control arm, and no masking, which keeps the design simple and closer to real-world practice, with the main purpose being to collect forward-looking medical data in a structured way.

The trial is not yet recruiting and was first submitted on March 12, 2026, signaling very early-stage activity. The latest update on March 17, 2026 confirms the plan is active and progressing through setup, even though primary and final completion dates are not yet posted.

For investors, this update supports Rocket’s long-term strategy in genetic cardiomyopathies rather than driving near-term revenue. It may modestly lift sentiment by showing execution in its BAG3 program, while also keeping the company in the competitive mix against other rare-cardiac gene therapy players focused on similar inherited heart diseases.

The BAG3-DCM natural history study from Rocket Pharmaceuticals is now moving forward in setup, and remains an ongoing, updated effort with more details available on the ClinicalTrials portal.

To learn more about RCKT’s potential, visit the Rocket Pharma drug pipeline page.